#JPM23: Did the IRA kill that drug?

Phar­ma com­pa­nies were loud and clear ahead of the pas­sage of Medicare price set­ting leg­is­la­tion in the In­fla­tion Re­duc­tion Act: Once passed, drugs that no longer worked in the new math of the leg­is­la­tion would need to be cut.

And with­in weeks of the law be­ing en­act­ed, we be­gan to see that hap­pen, with com­pa­nies like Eli Lil­ly and Al­ny­lam claim­ing ear­ly stage as­sets had to be shut down. Mov­ing for­ward, what’s to stop any com­pa­ny from claim­ing that every pipeline dele­tion is the re­sult of the IRA? How big will the im­pact re­al­ly be? What else should be ex­pect­ed? And are de­vel­op­ers sim­ply find­ing a con­ve­nient vil­lain to blame? Tune in be­low to find out more from the ex­perts.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.